Zacks Research Issues Pessimistic Estimate for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.19) for the quarter, down from their prior forecast of ($0.18). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.43) EPS.

A number of other equities analysts also recently issued reports on ESPR. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, March 20th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR opened at $1.50 on Friday. Esperion Therapeutics has a 1 year low of $1.47 and a 1 year high of $3.94. The stock has a market cap of $296.77 million, a P/E ratio of -2.34 and a beta of 1.04. The stock has a 50-day simple moving average of $1.78 and a 200-day simple moving average of $2.07.

Institutional Trading of Esperion Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ESPR. Wasatch Advisors LP grew its position in Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after purchasing an additional 6,483,070 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Esperion Therapeutics by 48.6% during the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock worth $6,862,000 after buying an additional 1,020,243 shares during the period. Bank of America Corp DE grew its holdings in shares of Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company’s stock worth $3,586,000 after buying an additional 506,428 shares during the last quarter. JPMorgan Chase & Co. increased its position in Esperion Therapeutics by 18.6% in the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company’s stock valued at $5,399,000 after acquiring an additional 385,099 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in Esperion Therapeutics during the 3rd quarter valued at approximately $606,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.